PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
646 episodes - English - Latest episode: 10 days ago - ★★★★ - 8 ratingsPeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Robert D. McBane, II, MD - Taking a New Look at Cancer-Associated Venous Thromboembolism: How Is Emerging Evidence Influencing Guidelines & Practice?
August 05, 2020 23:00 - 33 minutesGo online to PeerView.com/TGQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in venous thromboembolism (VTE) reviews the latest clinical science and guidelines pertaining to cancer-associated VTE prophylaxis and treatment. This video-based program also focuses on strategies to help learners prepare for the practical integration of direct oral anticoagulants (DOACs) in cancer-associated VTE and illustrates how...
"Robert D. McBane, II, MD - Taking a New Look at Cancer-Associated Venous Thromboembolism: How Is Emerging Evidence Influencing Guidelines & Practice?"
August 05, 2020 23:00 - 33 minutesGo online to PeerView.com/TGQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in venous thromboembolism (VTE) reviews the latest clinical science and guidelines pertaining to cancer-associated VTE prophylaxis and treatment. This video-based program also focuses on strategies to help learners prepare for the practical integration of direct oral anticoagulants (DOACs) in cancer-associated VTE and illustrates how...
Rebecca S. Heist, MD, MPH / Jacob Sands, MD - It’s Precisely the Time for More Precision in Genomic Testing and Targeted Treatment of NSCLC
August 04, 2020 23:00 - 1 hourGo online to PeerView.com/NEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, oncology experts discuss the roles of genomic testing and targeted treatment in lung cancer. Practical guidance for expanding molecular testing for genomic alterations occurring in non–small cell lung cancer with FDA-approved targeted therapies is explored. Upon completion of this activity, participants will be able to: Discuss the expanding r...
Matthew S. Johnson, MD, FSIR - Teaming Up to Improve Liver Cancer Outcomes Through Locoregional and Systemic Therapeutic Strategies: A Multidisciplinary Tumor Board Guiding Optimal Care for Patients Along the Intermediate to Advanced Disease Continuum
July 31, 2020 23:00 - 1 hourGo online to PeerView.com/DWV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hepatocellular carcinoma (HCC) is a complex liver malignancy for which a variety of treatment modalities, based on disease stage and patient factors, are available. Traditionally, interventional radiologists (IR) have had a key role in managing intermediate-stage disease through the use of locoregional approaches, while oncologists have employed systemic therap...
Joyce O’Shaughnessy, MD - Evidence Informing Practice: Changing Standards of Care for Use of CDK4 and 6 Inhibitors in the Treatment of Breast Cancer
July 30, 2020 23:00 - 1 hourGo online to PeerView.com/BKK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, breast cancer experts discuss the latest evidence on the use of CDK4 and 6 inhibitors in the management of patients with HR-positive, HER2-negative breast cancer. An essential overview of mechanisms of action of this therapeutic class, similarities/differences among the agents, and latest approvals/indications is provided, along with a summary...
Kimberly Halla, MSN, FNP-C - Rethinking Patient Care in Endometrial and Cervical Cancer: How Nurses Can Lead the Targeted and Immunotherapeutic Revolution
July 29, 2020 23:00 - 35 minutesGo online to PeerView.com/FDM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CNE activity, a family nurse practitioner brings the nurse’s perspective to patient care in endometrial and cervical cancer. Kimberly Halla, MSN, FNP-C, discusses modern management techniques for patient’s receiving targeted therapy and immunotherapy, as well as combination therapies, and gives her take on how to approach the unique safety profiles asso...
Sagar Lonial, MD, FACP - How I Think, How I Treat: Understanding Innovation in Multiple Myeloma—New Models for Attacking Disease Across the Clinical Spectrum
July 28, 2020 23:00 - 1 hourGo online to PeerView.com/XBQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert panel charts progress in myeloma care by discussing their personal experiences and insights, including analyses of how current evidence has informed the experts’ own practice along the disease continuum, from newly diagnosed to relapsed disease. This unique activity provides a link that connects novel agents to their applications in ...
Arjun Balar, MD - Innovative Treatments for Bladder Cancer: Thoughts From the Chair
July 27, 2020 23:00 - 25 minutesGo online to PeerView.com/YFM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this expert-led bladder cancer program, Dr. Arjun Balar discusses recent updates from the 2020 American Society of Clinical Oncology Annual Meeting and reviews new evidence on the continuing integration of novel therapeutics, including immunotherapy, targeted agents, and antibody-based approaches, across a wide range of bladder cancer treatment settings. Upo...
Sagar Lonial, MD, FACP - Fueling Innovation in Multiple Myeloma: Thoughts From the Chair
July 22, 2020 23:00 - 35 minutesGo online to PeerView.com/CSW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this program, a hematology-oncology expert discusses recent advances in multiple myeloma treatment, including highlights from the 2020 American Society of Clinical Oncology Annual Meeting; the expert focuses on important questions related to primary therapy in myeloma, including triplet and quadruplet therapy, as well as advances with antibody platforms, cel...
"Brendon Stiles, MD - Immunotherapy as a Component of Multimodal Therapy in Locally Advanced and Earlier Stages of Lung Cancer: Rationale, Evidence, and Implications for the Multidisciplinary Team"
July 20, 2020 23:00 - 1 hourGo online to PeerView.com/WHA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The evidence base for use of immunotherapy in lung cancer is expanding at a rapid pace, and immune checkpoint inhibition has become a new standard of care after chemoradiation in stage III, locally advanced, unresectable non–small cell lung cancer (NSCLC). The effectiveness of immunotherapy as a component of multimodal therapy has raised the possibility of furt...
Brendon Stiles, MD - Immunotherapy as a Component of Multimodal Therapy in Locally Advanced and Earlier Stages of Lung Cancer: Rationale, Evidence, and Implications for the Multidisciplinary Team
July 20, 2020 23:00 - 1 hourGo online to PeerView.com/WHA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The evidence base for use of immunotherapy in lung cancer is expanding at a rapid pace, and immune checkpoint inhibition has become a new standard of care after chemoradiation in stage III, locally advanced, unresectable non–small cell lung cancer (NSCLC). The effectiveness of immunotherapy as a component of multimodal therapy has raised the possibility of furt...
William K. Oh, MD - Chair’s Take on Innovation in Prostate Cancer: Thoughts on New Evidence
July 17, 2020 23:00 - 36 minutesGo online to PeerView.com/UPY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert oncologist will provide a brief recap of recent developments in prostate cancer, comment on these findings, and offer thoughts on how to integrate a range of novel therapeutics and optimally navigate patient care for those with prostate cancer. Upon completion of this activity, participants should be better able to: Examine the recen...
Harry P. Erba, MD, PhD - Advances in AML Care: Highlights From Recent Science
July 15, 2020 23:00 - 42 minutesGo online to PeerView.com/VKE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this program, a hematology-oncology expert discusses recent advances in the management of acute myeloid leukemia (AML), including highlights from the 2020 American Society of Clinical Oncology Annual Meeting. The expert also focuses on the relevance of such evidence for the management of diverse AML populations, including patients with high-risk or mutation-...
Professor Florence Cymbalista, MD, PhD - Transforming Care With BTK Inhibitors in CLL: New Insights on Therapy Selection, Safety, and Agent Sequencing Across the Treatment Continuum
July 13, 2020 23:00 - 1 hourGo online to PeerView.com/QHM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This activity features insights from leading clinicians on the evidence that links the underlying mechanistic principles of Bruton tyrosine kinase inhibition with lessons arising from major clinical studies of first- and second-generation BTK agents in the chronic lymphocytic leukemia (CLL) setting. Upon completion of this activity, participants should be bette...
Linda R. Duska, MD, MPH - Chair’s Take on Advances in Gynecologic Cancer Care: Exploring New Advances and Innovative Therapies in Endometrial and Cervical Cancers
July 10, 2020 23:00 - 34 minutesGo online to PeerView.com/VSK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Watch Dr. Duska provide a brief recap of recent developments in endometrial and cervical cancer management, including evidence presented at the 2020 American Society of Clinical Oncology Annual Meeting. Dr. Duska comments on these findings and offers thoughts on new and emerging strategies, including targeted, immune checkpoint inhibitor, antibody-based, and co...
Bradley J. Monk, MD, FACS, FACOG - Chair's Take: Latest and Emerging Evidence of PARP Inhibitors in Ovarian Cancer Management
July 08, 2020 23:00 - 28 minutesGo online to PeerView.com/VSY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert oncologist discusses recent developments in the use of PARP inhibitors and their companion diagnostics in advanced ovarian cancer and shares insight on incorporating PARP inhibitors into individualized treatment plans to improve patient outcomes in a variety of ovarian cancer settings. Upon completion of this activity, participants s...
David H. Ilson, MD, PhD - Chair's Take: HER2-Targeted and Other Agents for Gastric Cancer
July 06, 2020 23:00 - 34 minutesGo online to PeerView.com/GZH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert oncologist reviews the latest evidence and recent developments in gastric cancer care, including innovative targeted therapeutics, and offers strategies to optimally navigate patient care and integrate novel therapeutics into treatment plans. Upon completion of this activity, participants should be better able to: Describe the biolog...
Suresh S. Ramalingam, MD, FACP, FASCO - Chair's Take: Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer
July 03, 2020 23:00 - 28 minutesGo online to PeerView.com/WCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Suresh S. Ramalingam, MD, FACP, FASCO, provides a brief recap of the latest practice-changing data informing the use of an expanding arsenal of immune checkpoint inhibitors and combinations in NSCLC, as well as the evolving evidence on immunotherapies, transcription inhibitors, and other novel treatment approaches in SCLC. Upon completion of t...
Mitchell S. Cairo, MD - Achieving Consensus on Modern VOD/SOS Management: A Guide to Disease Recognition, Classification, and Treatment in Adults and Pediatric Patients
July 01, 2020 23:00 - 40 minutesGo online to PeerView.com/KAS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hematology discusses the recognition, classification, and treatment of adult and pediatric patients with veno-occlusive disease and sinusoidal obstruction syndrome. Upon completion of this activity, participants should be better able to: Cite updated recommendations and evidence on veno-occlusive disease/sinusoidal obstruction syn...
Brendon Stiles, MD - Chair's Take on Immunotherapy as a Component of Multimodal Therapy in Locally Advanced and Earlier Stages of Lung Cancer: Rationale, Evidence, and Implications for the Multidisciplinary Team
June 26, 2020 23:00 - 36 minutesGo online to PeerView.com/TYJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, Brendon Stiles, MD, provides a brief recap of the latest advances in the use of immunotherapy as a component of multimodal lung cancer care in locally advanced and earlier stages of NSCLC. He highlights some of the newest data from clinical trials and shares his perspective on the promise and implications of the transition of immune checkpoint...
Finding the Path to Clinically Meaningful Outcomes Among Expanding Treatment Options in Renal Cell Carcinoma
June 24, 2020 23:00 - 1 hourGo online to PeerView.com/KSB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this virtual educational activity, Hans Hammers, MD, PhD, provides expert insight on the renal cell carcinoma (RCC) treatment landscape, including an overview of the latest treatment options and safety concerns in frontline therapy, and the use of dual immune checkpoint inhibitors and immunotherapy-tyrosine kinase inhibitor combinations. He also leads a case...
Richard S. Finn, MD - Chair’s Take: Review of the Latest HCC Therapy Advancements
June 19, 2020 23:00 - 31 minutesGo online to PeerView.com/MAJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, expert Richard S. Finn, MD, recaps the most important developments in the management of patients with hepatocellular carcinoma (HCC), including new data presented at the American Society for Clinical Oncology 2020 Annual Meeting, and provides his perspective on how new and emerging treatment strategies can be incorporated into clinical practic...
Alok A. Khorana, MD, FACP, FASCO - Teaming Up to Reduce the Burden of Cancer-Associated VTE: Applying the Latest Guidelines and Evidence in Gastrointestinal and Hematologic Malignancies and Other Cancer Setting
June 15, 2020 23:00 - 31 minutesGo online to PeerView.com/MWJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Dr. Alok Khorana provide a brief recap of recent developments with DOACs in cancer-associated VTE, including evidence presented at the American Society of Clinical Oncology 2020 Annual Meeting. Dr. Khorana comments on these findings and offers thoughts on how to integrate novel oral anticoagulants for personalized management of patients with elevated-risk malig...
Robin Lachmann, MD, PhD / Melissa Wasserstein, MD - Assessing the Potential Role of Emerging Therapies in the Early Diagnosis and Optimal Management of Chronic Visceral Acid Sphingomyelinase Deficiency
June 12, 2020 23:00 - 1 hourGo online to PeerView.com/NPH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic visceral acid sphingomyelinase deficiency (ASMD), also referred to as Niemann-Pick disease type B, is a rare and progressive autosomal recessive lysosomal storage disorder that causes progressive accumulation of sphingomyelin and other lipids in tissues throughout the body and is associated with significant morbidity and reduced life expectancy. The dia...
Improving Outcomes in Patients With Molecularly Altered NSCLC Through Broad Implementation of Precision Testing and Treatment: Latest Evidence and Practical Guidance in the Context of a Changing Targeted Therapy Landscape
June 08, 2020 23:00 - 1 hourGo online to PeerView.com/NPG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, thoracic oncology experts discuss the expanding role of molecular testing and targeted treatment selection for patients with non–small cell lung cancer (NSCLC). The roles of tissue- and blood-based biomarker testing for mutations and other molecular alterations are explored, along with current data on the efficacy and safety of approved and in...
Nadeem Riaz, MD, MSc - Deep Insight Into Immuno-Oncology: A Visual Exploration of Current and Emerging Pathways, Targets, and Biomarkers to Maximize the Potential of Cancer Immunotherapies
June 05, 2020 23:00 - 1 hourGo online to PeerView.com/KNT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an immuno-oncology expert describes the basic biology of how the immune system responds to tumor activity, reviews the pathophysiology of the tumor microenvironment, provides up-to-date data supporting the use of cancer immunotherapies, including immune checkpoint inhibitors, and discusses investigational immuno-oncology pathways, putative tar...
Mike Janicek, MD / Bradley J. Monk, MD, FACS, FACOG - Targeting Pathogenic Mutations in the DNA Damage Response Pathway: Genetic Testing and Counseling in the Era of Precision Medicine and Next-Generation Sequencing
June 03, 2020 23:00 - 1 hourGo online to PeerView.com/XUK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Exploiting the impact of mutations in DNA damage response (DDR) pathways on tumorigenesis has led to advances in the development of targeted therapies such as poly-ADP ribose polymerase (PARP) inhibitors for patients with relevant cancers. These agents are currently approved for several indications and are under investigation in a number of other tumor types. I...
"Hope S. Rugo, MD, FASCO - Biosimilars as Partners in Oncology: Expert Guidance on Understanding and Incorporating Biosimilar Agents in Real-World Car"
May 18, 2020 23:00 - 1 hourGo online to PeerView.com/BBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a leading expert discusses key concepts in oncology and supportive care biosimilars, including how they are defined, the regulatory approval process for these agents, and an overview of data for biosimilars in the treatment and supportive care of cancer patients. Upon completion of this activity, participants will be able to: Describe the bios...
Hope S. Rugo, MD, FASCO - Biosimilars as Partners in Oncology: Expert Guidance on Understanding and Incorporating Biosimilar Agents in Real-World Car
May 18, 2020 23:00 - 1 hourGo online to PeerView.com/BBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a leading expert discusses key concepts in oncology and supportive care biosimilars, including how they are defined, the regulatory approval process for these agents, and an overview of data for biosimilars in the treatment and supportive care of cancer patients. Upon completion of this activity, participants will be able to: Describe the bios...
Bradley J. Monk, MD, FACS, FACOG - Expert Views on the Evolving Role of PARP Inhibitors in the Treatment of Ovarian Cancer
May 15, 2020 23:00 - 34 minutesGo online to PeerView.com/BBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss current evidence and clinical insights on the evolving role of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors in the frontline and recurrent maintenance settings in patients with ovarian cancer. Upon completion of this activity, participants should be better able to: Review the benefits of mai...
Farnaz Dadmanesh, MD - Increasing Importance of HER2 and HER3 Testing in the Context of an Expanding Targeted Therapies Landscape for Breast, Gastrointestinal, Lung, and Other Cancers: Latest Updates and Practical Guidance for Pathologists
May 11, 2020 23:00 - 1 hourGo online to PeerView.com/SMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the evolving era of precision cancer care, increasing emphasis is placed on detecting molecular alterations driving the development of specific cancers and targeting them with matched therapies or combinations that can yield the best outcomes for patients. Such is the case with HER2—and, more recently, also HER3 and TROP2—which are gaining growing interest a...
Sagar Lonial MD, FACP - Changing Perspectives on Multiple Myeloma and ASCT: Clinical Decision-Making, New Evidence, and Expanding Therapeutic Options
May 06, 2020 23:00 - 51 minutesGo online to PeerView.com/JHF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME-certified activity, which is based on a live symposium held adjunct to the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, features expert guidance on the rapidly changing clinical landscape in multiple myeloma (MM), grounding the recent changes in myeloma care squarely within the context of current recommendation...
Barbara Burtness, MD - Multimodal Head and Neck Cancer Care Meets the Immunotherapy Era: A Look at the Changing Nature of Multidisciplinary Collaboration and Integrated Treatment StrategiesMedia: Enduring Material
May 04, 2020 23:00 - 1 hourGo online to PeerView.com/QMH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this educational activity, based on a live event developed by PeerView and the Head and Neck Cancer Alliance and held at the 2020 Multidisciplinary Head and Neck Cancers Symposium, a panel of oncology and radiology professionals assess the latest evidence on immune checkpoint blockade as a part of a multipronged management approach to head and neck cancer (H...
"Barbara Burtness, MD - Multimodal Head and Neck Cancer Care Meets the Immunotherapy Era: A Look at the Changing Nature of Multidisciplinary Collaboration and Integrated Treatment StrategiesMedia: Enduring Material"
May 04, 2020 23:00 - 1 hourGo online to PeerView.com/QMH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this educational activity, based on a live event developed by PeerView and the Head and Neck Cancer Alliance and held at the 2020 Multidisciplinary Head and Neck Cancers Symposium, a panel of oncology and radiology professionals assess the latest evidence on immune checkpoint blockade as a part of a multipronged management approach to head and neck cancer (H...
William K. Oh, MD - Mapping the Pathways to Better Patient Outcomes in Prostate Cancer: Personal Insights and Guidance From the Patient CaseBook
May 01, 2020 23:00 - 1 hourGo online to PeerView.com/SEP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the prostate cancer management landscape has become increasingly complex with the approval of several second-generation anti-androgen therapies. Moreover, clinical trials of targeted therapies, immunotherapies, and novel combination regimens are underway across various forms of disease—including nonmetastatic castration-resistant prostate cance...
Richard S. Finn, MD - Developing a Therapeutic Game Plan for the Management of Hepatocellular Carcinoma: Expert Insights From the Patient CaseBook
April 29, 2020 23:00 - 1 hourGo online to PeerView.com/BXY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic management of hepatocellular carcinoma (HCC) has significantly evolved in recent years with the approvals of multikinase, antiangiogenic, and checkpoint inhibitors. Moreover, the treatment landscape is poised to broaden as emerging strategies focus on unmet clinical needs (eg, the use of combination regimens with immunotherapy and targeted agent...
Roy F. Chemaly, MD, MPH, FIDSA, FACP - Changing the Paradigm of CMV Management: New Science and More Choices for Challenging Cases in the HCT Setting
April 22, 2020 23:00 - 46 minutesGo online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valg...
Harry P. Erba, MD, PhD/James M. Foran, MD, FRCPC - The Continuing Wave of Innovation in AML: Getting the Most From the Convergence of Novel Therapy and Allogeneic Transplant
April 20, 2020 23:00 - 51 minutesGo online to PeerView.com/WRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent wave of therapeutic innovation in the management of patients with acute myeloid leukemia (AML) has had implications for many different patient populations, including those who are eligible for allogeneic hematopoietic stem cell transplantation (HCT). Most evidence currently supports a management model that includes the use of newer cytotoxic formulat...
Mitchell S. Cairo, MD - Following the Trail of Evidence in VOD Management: How Modern Risk Assessment, Diagnostic Principles, and Treatment Are Improving Care
April 17, 2020 23:00 - 52 minutesGo online to PeerView.com/DYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView’s latest CME-certified onDemand activity, based on a symposium at the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, experts lead a series of evidence-based “MasterClass” scientific discussions exploring the nuances of VOD risk assessment, diagnosis, and treatment. The experts also share their perspectives on several a...
Prithviraj Bose, MD / Jeanne M. Palmer, MD - State-of-the-Art Solutions for Myelofibrosis: The Intersection of JAK Inhibitors, Allogeneic Transplant, and Other Strategies for Patient Care
April 10, 2020 23:00 - 45 minutesGo online to PeerView.com/UQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts in the management of myelofibrosis (MF) offers learners an update on the modern diagnostic and risk assessment strategies that have informed a more considered treatment approach to symptomatic disease. An emerging paradigm, in which potentially curative hematopoietic cell transplantation (HCT) is used in conjunction with Jan...
Arjun Balar, MD - Advancing Bladder Cancer Care With Novel Therapeutics: Where We Are Headed With Immunotherapy, Targeted, and Antibody Options
April 08, 2020 23:00 - 1 hourGo online to PeerView.com/TYB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the emergence of immunotherapy as an essential component in the treatment armamentarium for bladder cancer, the therapeutic landscape for this disease has undergone significant transformation in recent years. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. These experts review the lates...
Carlos E. Bueso-Ramos, MD, PhD / Naval Daver, MD - Precision Diagnostics and Modern Therapy in AML: Innovation and Insights for Pathologists on Personalized Medicine and Team-Based Care
April 03, 2020 23:00 - 1 hourGo online to PeerView.com/AML20Live?Promocode=860 to view the activity, download slides and practice aids, and complete the post-test to earn credit.
Michael R. Bishop, MD - Taking the Leap With CAR T: Opportunities for Improving Care and Optimizing Cell Therapy in Hematologic Cancers
April 01, 2020 23:00 - 47 minutesGo online to PeerView.com/EAA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence and recent approval of a novel adoptive immunotherapy—chimeric antigen receptor (CAR) T cell therapy—offers hope for many patients underserved by standard options. Although initial regulatory approvals have occurred in diseases such as ALL and DLBCL, new evidence is suggesting that CAR T cells will play a role in the care of patients with clear me...
Kurt Schalper, MD, PhD - Leveraging Biomarkers to Guide Candidate Selection for Cancer Immunotherapies: Precision is Paramount, Collaboration is Crucial
April 01, 2020 23:00 - 1 hourGo online to PeerView.com/Precision20?Promocode=860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of malignancies, and as the immunotherapy arsenal has continued to expand, it has become clear that reliable biomarkers are needed to guide clinical decisions regarding treatment selection and identification of patients who are most likely to benefit...
Manish A. Shah , MD - Evidence and Practicalities: Checkpoint Inhibition in Gastrointestinal Cancers—Translating Recent Advances in Gastric, Esophageal, and Colorectal Cancers
March 30, 2020 23:00 - 1 hourGo online to PeerView.com/BJU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have become essential components of the treatment arsenal for gastrointestinal (GI) cancers, and ongoing studies are expected to further refine and expand their role. This video features a MasterClass from the 2020 GI Cancers Meeting in San Francisco where top GI specialists assessed the current state of the science and future poten...
Johanna C. Bendell, MD - How I Think, How I Treat—Personal Insights on Current Practices and Evolving Standards of Care in Pancreatic Cancer: Expert Perspectives on Implementing State-of-the-Art Care in the Clinic
March 27, 2020 23:00 - 1 hourGo online to PeerView.com/QAF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovations in the management of pancreatic cancer have increased hope for patients with this aggressive malignancy. New and promising treatment advances include novel chemotherapy platforms, such as gemcitabine/nab-paclitaxel and nanoliposomal irinotecan–based regimens; targeted systemic approaches, including PARP inhibitors, stroma-targeting agents, and immun...
Arjun Balar, MD - Raising the Bar With Innovative Therapy for Bladder Cancer: Insights on Clinical Decision-Making in the New Era of Care
March 27, 2020 23:00 - 1 hourGo online to PeerView.com/MJJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, developed in collaboration with the Bladder Cancer Advocacy Network, a panel of leading bladder cancer experts pair important analyses of the latest evidence on a new generation of therapeutics with practical insights that can be used to guide decision-making in the clinic. The panel also provides guidance on how to manage several challenging ...
Milind Javle, MD - Blazing the Therapeutic Management Trail of Biliary Cancers: Get Prepared for a New Era of Molecular- and Mutation-Driven Treatments
March 09, 2020 23:00 - 1 hourGo online to PeerView.com/YTB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The rarity and heterogeneity of biliary cancers (eg, cholangiocarcinoma, gallbladder cancer) make this group of malignancies a clinical challenge in GI oncology. Fortunately, recent scientific developments on the genetic and molecular level have led to the clinical testing of several targeted agent classes, including FGFR, IDH, HER2, TRK, and multikinase inhibi...
Jerry Vockley, MD, PhD - Novel Strategies and Emerging Evidence to Address Unmet Needs in Treating Patients With Long-Chain Fatty Acid Oxidation Disorders
March 04, 2020 23:00 - 30 minutesGo online to PeerView.com/QXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in medical genetics and inborn metabolism errors discusses novel strategies and emerging evidence for the identification and management of patients with long-chain fatty acid oxidation disorders. Upon completion of this activity, participants should be better able to: Recognize the signs and symptoms associated with the clinical pres...
Marianne Davies , DNP, ACNP, AOCNP - Maximizing the Benefits and Minimizing the Risks of Cancer Immunotherapies in Everyday Oncology Practice: Need-to-Know Information and Practical Guidance for Oncology Nurses
March 02, 2020 23:00 - 1 hourGo online to PeerView.com/WUA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an oncology nurse practitioner and expert in immuno-oncology provides a comprehensive overview of cancer immunotherapies, including how the immune checkpoint inhibitors work, their efficacy and safety profiles, and the latest approvals and indications. In addition, practical guidance for determining candidates for immune checkpoint inhibitor t...